BACKGROUND Intrauterine contraception is a first-line option for young women, yet relatively few prospective studies have been performed in nulliparous women using currently available devices, and many providers are still reluctant to provide this option. METHODS Between January 2012 and June 2014, 109 nulliparous women, aged 18-30 years, who had an intrauterine device (IUD) placed at a stude...

Introduction: Pregnant leukemia patients should be offered continuation or termination of pregnancy. Treatment in reproductive-age includes consideration contraception. Hormonal intrauterine devices (IUDs) prevent pregnancy and decrease menstrual bleeding. Despite safety data for IUDs immunocompromised patients, infection vaginal bleeding concerns may inhibit their placement. Case Report: We re...

PurposeIntrauterine levonorgestrel (LNG-IUD) is used to treat patients with endometrial adenocarcinoma (EAC) and hyperplasia atypia (EHA) but limited evidence available on its effectiveness. The study determined the extent which LNG-IUD or without metformin (M) weight loss (WL) achieves a pathological complete response (pCR) in EAC EHA.Patients methodsThis phase II randomized controlled clinica...

BACKGROUND We aimed to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the uterine vasculature and the endometrium. METHODS The study was a prospective controlled study evaluating the local effects of LNG-IUS compared with the copper intrauterine device (IUD). Forty-seven women carrying LNG-IUS (group A) were compared with 35 women carrying copper IUD in a...

Journal of Family Planning and Reproductive Health Care 2004: 30(2) What is the levonorgestrel-releasing intrauterine system? This Guidance provides recommendations and good practice points regarding the use of a levonorgestrelreleasing intrauterine system, the accepted abbreviation for which is LNG-IUS. The use of a copper-bearing intrauterine device (IUD) has been covered in previous Faculty ...

To our knowledge, no studies have specifically sought to understand the use of long-acting reversible contraception (LARC) by gender diverse adolescents and young adults (AYA). We describe characteristics AYA seeking LARC, indications for placement, complications, side effects continuation/removal rates. This retrospective cohort study included age 13-26 years LARC from three U.S. Adolescent Me...

OBJECTIVE To review the endometrial safety and patient acceptability of long-term use of continuous transdermal estrogen substitution combined with intrauterine release of levonorgestrel (LNG) in postmenopausal women. DESIGN One-hundred and fifty-three women who utilized the regimen for 2 IUD cycles were followed-up for a period of 10 years. Histology of the endometrium was evaluated at the e...